SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)
Clin. transl. oncol. (Print)
; 25(9): 2707-2717, sept. 2023. ilus, tab
Article
in English
| IBECS
| ID: ibc-224135
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin, and a paradigmatic model for a successful rational development of targeted therapies in cancer. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. These guidelines are elaborated by the conjoint effort of the Spanish Society of Medical Oncology (SEOM) and the Spanish Sarcoma Research Group (GEIS) and provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers (AU)
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Gastrointestinal Stromal Tumors
Limits:
Humans
Country/Region as subject:
Europa
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2023
Document type:
Article
Institution/Affiliation country:
Hospital General Universitario Gregorio Marañón/Spain
/
Hospital Universitario Basurto/Spain
/
Hospital Universitario Clínico San Carlos/Spain
/
Hospital Universitario Fundación Jiménez Díaz/Spain
/
Hospital Universitario Virgen de la Arrixaca/Spain
/
Hospital Universitario la Paz/Spain
/
Hospital de la Santa Creu I Sant Pau/Spain
/
Hospital Álvaro CunqueiroComplejo Hospitalario Universitario de Vigo/Spain
/
Hospitales Universitarios Regional y Virgen de la Victoria/Spain
/
Vall dHebron Barcelona Hospital Campus/Spain